Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20645767 | 0.89 | RIPK1 (0.38) | RIPK1SMN1; SMN2 | |
| SCHEMBL20645808 | 0.81 | MAPK1 (0.36) | RIPK1SMN1; SMN2 | |
| SCHEMBL19659321 | 0.79 | ALDH1A1 (0.33) | RIPK1SMN1; SMN2 | |
| SCHEMBL23256256 | 0.77 | HTT (0.35) | SMN1; SMN2 | |
| SCHEMBL20645939 | 0.77 | RIPK1 (0.44) | RIPK1SMN1; SMN2 | |
| SCHEMBL20228866 | 0.77 | RIPK1 (0.44) | RIPK1SMN1; SMN2 | |
| SCHEMBL20228736 | 0.75 | RIPK1 (0.35) | RIPK1SMN1; SMN2 | |
| SCHEMBL20646022 | 0.73 | RIPK1 (0.50) | RIPK1 | |
| SCHEMBL20645781 | 0.73 | RIPK1 (0.41) | RIPK1SMN1; SMN2 | |
| SCHEMBL20645952 | 0.73 | RIPK1 (0.41) | RIPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |